• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Aruna Bio

Monday, June 03, 2024
CP
CNS/Neurological
Aruna Bio is advancing neural exosome therapies for neurodegenerative diseases. Leveraging its proprietary platform and manufacturing, the company aims to develop treatments that cross the blood-brain barrier to promote anti-inflammatory responses and self-repair in conditions lacking effective solutions. Aruna has gained FDA clearance for its first IND, AB126, targeting acute ischemic stroke - a pioneering step for exosome-based therapy in neurology. AB126 also shows promise for chronic conditions like ALS, evidenced by positive data in an SOD1 murine model. The platform's versatility allows integration with other therapeutics, enhancing delivery across the blood-brain barrier directly to disease sites.
Aruna Bio
Company Website: https://www.arunabio.com/
Lead Product in Development: AB126 neural exosome
Number Of Unlicensed Products (For Which You Are Seeking Partners): one

Website

https://www.arunabio.com/

Company HQ City

Athens

Company HQ State

GEORGIA

Company HQ Country

United States

CEO/Top Company Official

Stephen From

Lead Product in Development

AB126 neural exosome

Development Phase of Primary Product

Phase I
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS